Showing 1 - 9 of 9 Items
Showing 1 - 9 of 9 Items
Sort By: Relevance
Journal Article
|Research
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Journal Article
|Research
2022-02-01 • International Journal of Tuberculosis and Lung Disease
2022-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Journal Article
|Research
2022-01-31 • Tropical Medicine and Infectious Disease
2022-01-31 • Tropical Medicine and Infectious Disease
Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was inte...
Journal Article
|Research
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...
Journal Article
|Research
2018-09-14 • PLOS One
2018-09-14 • PLOS One
BACKGROUND
Self-administered treatment (SAT), a differentiated model of care for rifampicin-resistant tuberculosis (RR-TB), might address adherence challenges faced by patients and h...
Self-administered treatment (SAT), a differentiated model of care for rifampicin-resistant tuberculosis (RR-TB), might address adherence challenges faced by patients and h...
Journal Article
|Research
2020-03-01 • eClinicalMedicine
2020-03-01 • eClinicalMedicine
BACKGROUND
Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10-19...
Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10-19...
Journal Article
|Letter
2020-07-23 • European Respiratory Journal
2020-07-23 • European Respiratory Journal
Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partner...
Journal Article
|Research
2018-05-03 • European Respiratory Journal
2018-05-03 • European Respiratory Journal
Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We describe early efficacy and safety data from a programmatic setting in South Africa. This was ...
Journal Article
|Letter
2020-07-01 • European Respiratory Journal
2020-07-01 • European Respiratory Journal